摘要
目的:系统评价荆花胃康胶丸联合三联疗法治疗幽门螺杆菌(Hp)相关性慢性胃炎或消化性溃疡的有效性和安全性,为临床提供循证参考。方法:计算机检索Medline、PubMed、Embase、ISI Web of Science、中国知网、万方等数据库,收集荆花胃康胶丸联合三联疗法对比三联疗法或联用铋剂的四联疗法治疗Hp相关性慢性胃炎或消化性溃疡的随机对照试验(RCT),筛选文献、提取资料,采用改良的Jadad量表评价文献质量,并采用RevMan 5.0软件进行Meta分析。结果:共纳入22项RCT,包含3 069例患者。Meta分析结果显示,相比三联疗法组,荆花胃康胶丸+三联疗法组在Hp根除率[OR=1.96,95%CI(1.47,2.60),P<0.001]、消化道症状缓解率[OR=1.75,95%CI(1.27,2.41),P<0.001]方面更优,差异均有统计学意义,但不良反应发生率与之比较差异无统计学意义[OR=0.67,95%CI(0.36,1.25),P=0.21];荆花胃康胶丸+三联疗法组患者的Hp根除率[OR=0.97,95%CI(0.75,1.26),P=0.83]、消化道症状缓解率[OR=1.37,95%CI(0.97,1.94),P=0.07]与四联疗法组比较,差异均无统计学意义,但荆花胃康胶丸+三联疗法组患者的不良反应发生率显著低于后者,差异有统计学意义[OR=0.25,95%CI(0.15,0.44),P<0.001]。结论:荆花胃康胶丸联合三联疗法相比三联疗法能显著提高患者Hp根除率和消化道症状缓解率,相比四联疗法能显著降低其不良反应发生率。
OBJECTIVE:To evaluate efficacy and safety of Jinghua weikang capsules combined with triple therapy in the treatment of Helicobacter pylori(Hp) related chronic gastritis or peptic ulcer,and to provide evidenle-based reference in clinic.METHODS:Retrieved from Medline,PubMed,Embase,ISI Web of Science,CNKI and Wanfang database,RCTs about Jinghua weikang capsules combined with triple therapy versus traditional triple therapy or quadruple therapy which combined with bismuth in the treatment of Hp related chronic gastritis or peptic ulcer were collected. After literature screening and data extraction,the quality of literatures were evaluated by using modified Jadad scale. Meta-analysis was performed by using RevMan 5.0 statistical software. RESULTS:A total of 22 RCTs were included,including 3 069 patients. Results of Meta-analysis showed that compared with triple therapy group,Jinghua weikang capsules combined with triple therapy group was better in Hp eradication rate [OR=1.96,95%CI(1.47,2.60),P〈0.001] and remission rate of digestive tract symptoms [OR=1.75,95%CI(1.27,2.41),P〈0.001],with statistical significance;but there was no statistical significance in the incidence of ADR in 2 groups [OR=0.67,95%CI(0.36,1.25),P=0.21]. There was no statistical significance in Hp eradication rate [OR=0.97,95%CI(0.75,1.26),P=0.83] and remission rate of digestive tract symptoms [OR=1.37,95% CI(0.97,1.94),P=0.07] in Jinghua weikang capsules combined with triple therapy group and quadruple therapy group,but the incidence of ADR in Jinghua weikang capsules combined with triple therapy group was lower than quadruple therapy group, with statistical significance [OR=0.25,95% CI(0.15,0.44),P〈0.001].CONCLUSIONS:Compred with triple therapy,Jinghua weikang capsules combined with triple therapy can improve the rates of Hp eradication and digestive tract symptom remission. Compared with quadruple therapy,it can reduce the incidence of ADR.
作者
阴瑞瑞
陈海亮
武鑫
杨洁
王琦
YIN Ruirui;CHEN Hailiang;WU Xin;YANG Jie;WANG Qi(Dept.of Gastroenterology,Second Hospital ofShanxi Medical University,Taiyuan 030001,China)
出处
《中国药房》
CAS
北大核心
2018年第16期2256-2260,共5页
China Pharmacy
基金
国家自然科学基金青年基金资助项目(No.81602176)